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Abstract
Activation of peroxisome proliferator-activated receptor-c (PPARc) inhibits growth of cancer cells including non-small cell
lung cancer (NSCLC). Clinically, use of thiazolidinediones, which are pharmacological activators of PPARc is associated with a
lower risk of developing lung cancer. However, the role of this pathway in lung cancer metastasis has not been examined
well. The systemic effect of pioglitazone was examined in two models of lung cancer metastasis in immune-competent
mice. In an orthotopic model, murine lung cancer cells implanted into the lungs of syngeneic mice metastasized to the liver
and brain. As a second model, cancer cells injected subcutaneously metastasized to the lung. In both models systemic
administration of pioglitazone increased the rate of metastasis. Examination of tissues from the orthotopic model
demonstrated increased numbers of arginase I-positive macrophages in tumors from pioglitazone-treated animals. In co-
culture experiments of cancer cells with bone marrow-derived macrophages, pioglitazone promoted arginase I expression
in macrophages and this was dependent on the expression of PPARc in the macrophages. To assess the contribution of
PPARc in macrophages to cancer progression, experiments were performed in bone marrow-transplanted animals receiving
bone marrow from Lys-M-Cre+/PPARc
flox/flox mice, in which PPARc is deleted specifically in myeloid cells (PPARc-Mac
neg), or
control PPARc
flox/flox mice. In both models, mice receiving PPARc-Mac
neg bone marrow had a marked decrease in secondary
tumors which was not significantly altered by treatment with pioglitazone. This was associated with decreased numbers of
arginase I-positive cells in the lung. These data support a model in which activation of PPARc may have opposing effects on
tumor progression, with anti-tumorigenic effects on cancer cells, but pro-tumorigenic effects on cells of the
microenvironment, specifically myeloid cells.
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Introduction
Lung cancer is the leading cause of cancer deaths in both men
and women worldwide, and survival rates remain low [1]. A
principal reason is that many patients present with advanced
disease and metastases at the time of diagnosis. Therefore,
translational studies designed to identify pharmaceuticals that
inhibit metastasis are essential to improving clinical outcomes.
Although genetic changes in cancer cells drive tumor initiation, the
tumor microenvironment plays a critical role in tumor progression
and metastasis [2]. Interactions between tumor cells and cells in
the tumor microenvironment (e.g. vascular cells, immune cells,
fibroblasts) control tumor angiogenesis and can promote a more
aggressive phenotype. These cell-cell interactions are mediated
through cytokines and growth factors initially produced by the
tumor cells, which result in immune and vascular cell recruitment.
The role of the tumor microenvironment in lung cancer has not
been as extensively studied as in other types of cancer, such as
breast and prostate, at least in part because of the lack of good
animal models. Chemical carcinogenesis models have been
important in studying tumor initiation, but the resulting tumors
are usually adenomas which do not metastasize. Genetic mouse
models have also been employed, but although these form
adenocarcinomas, they are often weakly metatastic [3]. Studies
with human lung cancer cell lines have used xenograft models
in which tumor cells are inoculated subcutaneously into immuno-
compromised rodents. Thus the environment in which the
primary tumor develops is not the lung, and the full role of
immune cells on tumor progression cannot be assessed. We have
therefore developed an orthotopic model in which mouse tumor
cells derived from lung tumors in C57BL/6 mice [4] are directly
injected into lungs of syngeneic mice [5], allowing an assessment of
tumor progression and metastasis in immunocompetent animals.
This provides a clinically relevant system in which to test the
efficacy of new strategies/pharmaceuticals designed to target lung
cancer progression and metastasis.
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member of the nuclear hormone receptor superfamily of ligand-
activated transcription factors [6]. The classic pathway of
PPARcactivation involves binding as a heterodimer with the
retinoic acid X receptor to specific DNA sequences in the
promoters of target genes. Ligand binding causes a conformational
change, resulting in the release of co-repressors and the binding of
co-activators. PPARc has also been shown to bind to other
transcription factors resulting in transrepression [6]. Endogenous
PPARc activators include polyunsaturated fatty acids and
eicosanoids, while synthetic activators of PPARc include the
thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone
[7]. It has been well documented that PPARc activation plays
a critical role in adipocyte activation and differentiation. Recently,
however, PPARc has also been implicated in regulating multiple
types of cancer, including lung cancer. Analysis of human lung
tumors has reported that decreased expression of PPARc is
correlated with a poor prognosis [8]. Importantly, a retrospective
study examining cancer incidence in diabetic patients using TZDs
demonstrated a 33% reduction in lung cancer risk [9], with an
even more dramatic reduction in African-American diabetic
patients (75%). This decreased risk was specific for lung cancer,
with no protective effect observed for prostate or colon cancer.
Preclinical studies from our laboratory demonstrated that
activation of PPARc in human non-small cell lung cancer cell
(NSCLC) lines inhibited transformed growth and invasiveness, and
promoted a more differentiated phenotype [10,11]. Furthermore
targeted overexpression of PPARc in mice to distal type II alveolar
epithelial cells had chemopreventive effects by inhibiting the
initiation of lung tumors [12]. Collectively, these studies suggest
that targeting PPARc may have important chemopreventive
applications for lung cancer. However, the role of PPARc
activation by systemic administration of TZDs in regulating tumor
progression and metastasis of lung cancer has not been well
studied. In fact, the retrospective clinical study which showed
decreased incidence of lung cancer in diabetics treated with TZDs
excluded individuals who had a pre-existing diagnosis of cancer
[9]. The goal of our study was to determine the effect of systemic
PPARc activation on lung cancer progression and metastasis using
the TZD pioglitazone in our orthotopic immunocompetent model.
In contrast to our original hypothesis that pioglitazone would exert
protective effects on lung cancer metastasis, here we report the
unexpected findings that systemic administration of pioglitazone
accelerates the rate of lung tumor progression and metastasis, and
this is mediated through activation of PPARcin myeloid cells.
Results
Pioglitazone-fed mice exhibit increased lung cancer
progression and metastasis
To assess the effect of systemically administered pioglitazone on
lung cancer progression and metastasis in immune-competent
mice we used CMT/167 cells, a lung adenocarcinoma cell line
derived from C57BL/6 mice [13]. We have previously shown that
injection of these cells into the lungs of syngeneic C57BL/6 mice
results in a primary tumor, which subsequently progresses to form
secondary pulmonary tumors, and metastasizes to the lymph
nodes and distant organs [5]. In vitro experiments demonstrated
that pioglitazone inhibits invasiveness of these cells (Figure S1),
and promotes a more differentiated phenotype in 3-dimensional
Matrigel cultures (Figure S1), consistent with what we have
observed with PPARc activation in human NSCLC [10]. To
examine the systemic role of PPARc in vivo wild-type C57BL/6
mice were placed on control or pioglitazone-impregnated chow 7
days prior to cancer cell injections and throughout the course of the
experiment. After 7 days, cancer cells stably expressing luciferase
(CMT/167-luc) suspended in Matrigel (BD Biosciences) were
injected through the rib cage into the left lobe of mice as
previously described [5]. Primary tumor formation was analyzed 3
days after injections by in vivo bioluminescent imaging; mice that
did not show the development of a primary tumor were removed
from the study. At various times after injections, mice were
sacrificed and lungs, heart, liver, and brains removed for ex vivo
bioluminescence imaging and histological analysis. Examination of
H&E stained lung sections revealed large primary tumors and the
presence of cancer cell intravasation into blood vessels adjacent to
primary tumors as well as cancer cell extravasation from blood
vessels in other lung lobes (Figure 1A). Growth of the primary
tumor was not significantly different between the two groups of
mice (Figure 1B). In contrast, pioglitazone-fed mice exhibited
markedly increased numbers of secondary pulmonary metastases,
which were determined by counting number of tumors in H&E
lung sections (Figure 1C). Incidence of liver and brain metastases
was quantified at 25–30 days post-injection by ex vivo biolumi-
nescent imaging. The incidence of liver metastases in pioglitazone-
treated mice was twice that of the control group (Figure 1D,E). In
the pioglitazone-treated group approximately 10% of the animals
developed brain metastases, while no brain metastases were
detected in the control group (Figure 1D,F). Overall survival was
not different in the two groups of mice (Figure 1G). To validate
that mice fed pioglitazone-impregnated chow received the drug
and that PPARc was being activated, serum was collected and
adiponectin levels were measured by ELISA. As has been
previously published [14], serum adiponectin levels were increased
within 7 days of pioglitazone administration, and remained
elevated after 23 days (Figure 1H).
Systemically administered pioglitazone increases the
numbers of arginase I-positive macrophages within
tumors
Recruitment of bone marrow–derived cells, and in particular
monocytes/macrophages, contributes to the tumor microenviron-
mentandisassociated withmore aggressive,malignanttumors[15].
To characterize the effectsofsystemic PPARc activationinduced by
pioglitazone on bone marrow cell recruitment and tumor
progression, WT mice received bone marrow transplants from
UBI-EGFP/B6 transgenic donors, which express EGFP in all cells.
After allowing 6 weeks for recovery, animals were placed on
appropriate chow for 7 days, and then injected with CMT/167-luc
cells. Animals were maintained on either pioglitazone-impregnated
or control chow throughout the course of the experiment. Lung
sectionswere examinedforGFP,Mac3andarginaseIexpression by
triple immunofluorescence to verify recruitment of bone marrow-
derived macrophages and to determine if recruited macrophages
are polarized to express an alternative M2, anti-inflammatory
phenotype. Both groups of mice exhibited notable numbers of
GFP(+) Mac3(+) cells surrounding the tumor (Figure 2A; represen-
tative image from pioglitazone-fed lung section), indicating that the
majority of the recruited bone marrow cells are macrophages. In
addition, we found that the vast majority of arginase I-positive cells
within and surrounding tumors were Mac3(+) macrophages
(Figure 2A). Tumor-associated macrophages (TAMs) were quanti-
fied by counting Mac3(+) cells in primary tumors of both groups
of mice. Although no differences in the overall number of
macrophages surrounding primary lung tumors were found
between the two groups of mice used in our orthotopic lung
experiment (data not shown), the number of arginase I-positive
macrophages within primary tumors was markedly increased in
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28133Figure 1. Pioglitazone accelerates CMT/167 tumor progression and metastasis in an orthotopic mouse model of NSCLC. Wild-type
C57BL/6 mice were fed either normal chow or chow impregnated with pioglitazone (0.05%) for 1 week prior to tumor cell implantation and
throughout the course of the experiment. CMT/167-luc cells (10
5) were orthotopically injected into the left lung as described in the Methods section.
Lungs, livers, and brains were harvested 25–30 days post-injection. A. Hematoxylin-eosin stained sections of tumor-bearing lungs. Arrows indicate
primary or secondary lung tumors, as well as tumors intravasating into or extravasating out of a blood vessel. B. Quantitation of primary tumor
diameter in control (n=17) and pioglitazone-treated (n=16) animals measured using digital calipers. C. Number of secondary pulmonary tumors in
C57BL/6 mice fed either normal chow or pioglitazone chow were determined by quantifying tumors in hematoxylin-eosin stained sections through
the middle of the lungs. Data are means and s.d. of counts from 12-16 animals in each group. D. Percentage of C57BL/6 mice fed either normal chow
(n=17) or pioglitazone-impregnated chow (n=16) with liver and brain metastases. Liver and brain metastases were identified by ex vivo
bioluminescent imaging of organs at the time of sacrifice and were confirmed by histology. E. Representative bioluminescent images of liver
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of tumor cells (Figure 2B).
Pioglitazone promotes an ‘‘M2’’ pro-tumorigenic
macrophage phenotype in co-cultures of cancer cells and
macrophages
To determine whether PPARc plays a role in macrophage M2
polarization, bone marrow cells isolated from wild type C57BL/6
male mice were grown in the presence of recombinant M-CSF to
promote differentiation into macrophages [16]. These cells have
the morphology of macrophages, are .95% F4/80 positive, and
do not express notable levels of either iNOS or arginase I, markers
of M1 and M2 macrophage phenotypes respectively [17].
Stimulation of these cells with IL-4 induced arginase I expression,
consistent with an M2 phenotype (Figure 2C). To examine the
effects of pioglitazone on interactions between cancer cells and
macrophages, bone marrow-derived macrophages were co-
cultured with CMT/167 cells for three days in the absence or
presence of pioglitazone (10 mM) using Transwells which allow
diffusible mediators to act on each cell type. CMT/167 cells
selectively induced expression of arginase I in macrophages
(Figure 2D), with no effect on iNOS expression (not shown).
Pioglitazone as a sole agent did not affect expression of either
arginase I or iNOS. However, arginase I expression was enhanced
in co-cultures treated with pioglitazone (Figure 2D).
To define the contribution of PPARc in macrophages to
induction of arginase I, bone marrow-derived macrophages were
isolated from Lys-M-Cre6PPARc
flox/flox mice, in which PPARc is
selectively deleted in myeloid lineages (PPARc-Mac
neg), or control
mice (PPARc
flox/flox) mice. Expression of PPARc was undetectable
in macrophages from PPARc-Mac
neg mice, while WT and
PPARc
flox/flox had comparable levels of expression (Figure 2E).
Importantly, co-cultures of CMT/167 cells with PPARc-Mac
neg
macrophages resulted in lower levels of arginase I expression in
these macrophages compared to control macrophages (Figure 2F).
These data indicate that activation of PPARc in macrophages
collaborates with signals from cancer cells to promote the M2
phenotype. It should be noted that pioglitazone still modestly
increased arginase I expression in the PPARc-Mac
neg macro-
phages, suggesting some contribution of PPARc-independent
‘‘off-target’’ effects.
Targeted deletion of PPARc in macrophages inhibits
metastasis
To assess the role of PPARc in macrophages in vivo, we
performed bone marrow transplants, in which WT mice received
bone marrow transplants from either PPARc-Mac
neg or control
PPARc
flox/flox donors. Six weeks after transplantation, animals
were placed on pioglitazone-impregnated or control chow for
7 days, followed by implantation of 10
5 CMT/167-luc cells into
the lung. Animals were maintained on either pioglitazone-
impregnated or control chow until they were sacrificed 4 weeks
after tumor implantation. Secondary pulmonary tumors were
quantified by counting visible metastases under a dissecting
microscope and confirmed by histology. As shown in Figure 3A,
the number of secondary pulmonary tumors was greatly inhibited
in all of the mice receiving bone marrow from PPARc-Mac
neg
mice. Pioglitazone increasedsecondarylung tumorsincontrolmice,
consistent with our findings in untransplanted mice. However,
pioglitazone did not significantly increase the number of lung
metastases in mice transplanted with bone marrow from PPARc-
Mac
neg mice (Figure 3A). Representative histology of the secondary
lung tumors is shown in Figure 3B. Average size of the metastases
was not significantly different in any of the four groups (data not
shown). We examined arginase I positive macrophages in the lungs
of tumor bearing animals. Pioglitazone did not alter the number of
arginase I-positive cells in control PPARc
flox/flox lungs. However,
lungs from PPARc-Mac
neg mice on control chow showed a
statistical decrease in arginase I positive cells; pioglitazone increased
the number of these cells to levels seen in PPARc
flox/flox mice
(Figure 3C,D). In all cases the great majority of arginase I positive
cells stained positive for macrophage markers (data not shown).
To confirm the findings in our orthotopic model, we employed
a second model in which tumor cells were implanted subcutane-
ously in the flanks of C57BL/6 mice fed either normal or
pioglitazone-impregnated chow. We used WT C57BL/6 mice
transplanted with bone marrow from either PPARc-Mac
neg mice
or control PPARc
flox/flox mice. Six weeks after transplantation,
animals were placed on pioglitazone-impregnated or control chow
for 7 days, followed by implantation of 10
5 CMT/167-luc cells
into the flank. Animals were maintained on either pioglitazone-
impregnated or control chow until they were sacrificed 4 weeks
after tumor implantation. Primary tumor size was measured with
digital calipers and lung metastases were quantified by counting
visible metastases under a dissecting microscope and confirmed by
histology. As shown in Figure 4A, primary tumor volume was
similar in PPARc
flox/flox mice in the presence or absence of
pioglitazone, as well as in PPARc-Mac
neg mice on control chow;
PPARc-Mac
neg mice receiving pioglitazone exhibited a modest
decrease in primary tumor size. Importantly and similar to our
orthotopic model, pioglitazone markedly increased lung metasta-
ses in PPARc
flox/flox mice compared to control chow-fed
PPARc
flox/flox mice (Figure 4B). In contrast, pioglitazone failed
to significantly increase the number of lung metastases in PPARc-
Mac
neg mice (Figure 4B). Representative histology of the lung
metastases is shown in Figure 4C. Average size of the metastases
was not significantly different in any of the four groups (data not
shown). Overall, we have not observed a correlation between
primary tumor size and metastasis in any of the models we have
studied. In addition, and similar to the orthotopic model,
pioglitazone did not alter the number of arginase I-positive cells
in the lungs of PPARc
flox/flox mice. However, the number of
arginase I-positive cells was significantly decreased in PPARc-
Mac
neg mice, both under control conditions and in the presence
of pioglitazone (Figure 4D,E). Finally, to determine if effects on
metastasis were specific to pioglitazone, experiments were
repeated using chow impregnated with rosiglitazone, another
TZD. Exposure to rosiglitazone showed similar increases in
incidence of metastasis, but no change in primary tumor volume
(Figure S2).
Discussion
Non-small cell lung carcinoma (NSCLC) accounts for the
majority of cases of lung cancer, which is the leading cause of
metastases in mice fed either normal chow (upper left panel) or pioglitazone-impregnated chow (upper right panel). Representative bioluminescent
images of brains from mice fed either normal chow (lower left panel) or pioglitazone-impregnated chow (lower right panel). F. Kaplan-Meier survival
curve of C57BL/6 mice injected with CMT/167-luc cells fed either control or pioglitazone-impregnated chow. G. Mean serum concentrations of
adiponectin in C57BL/6 mice fed either normal chow or pioglitazone-impregnated chow. For all graphs *P,0.05 vs Control.
doi:10.1371/journal.pone.0028133.g001
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28133Figure 2. Effect of pioglitazone on cells in the tumor microenvironment. A. Representative immunofluorescent staining for GFP (a), Mac3
(b), arginase I (c), and the overlay of all three with DAPI (d) in a primary tumor and surrounding tissue 16 days after cancer cell injection from a
pioglitazone-treated recipient mouse that received a bone marrow transplant from a UBI-EGFP transgenic donor. The asterisk indicates the tumor. B.
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treatment of lung cancer are urgently needed. Based on
retrospective clinical studies [9], there is considerable interest in
the use of TZDs as potential chemopreventive or chemotherapeutic
agents in the treatment of lung cancer. This is supported by
extensive studies demonstrating the effects of PPARc activation in
cancer cells on inhibition of transformed growth [18], induction of
apoptosis [19,20], and promotion of differentiation [10,21]. In
Quantitation of arginase I-positive cells within the tumors 16 days after injection. Data are means and s.e.m. of counts from 11–13 animals in each
group, using 1–2 slides per animal and counting 4 random fields per slide. *P,0.05 vs Control. C. Bone marrow-derived macrophages isolated as
described in the Methods section were stimulated for 18 hours with either IFNc/LPS or IL-4 and analyzed for expression of arginase I. D. Identical cells
from (C) were grown alone or in co-culture with CMT/167 cells for 3 days in the absence or presence pioglitazone (10 mM). Cell lysates were
immunoblotted for arginase I. E. Whole cell lysates from WT, PPARc
flox/flox (Fl/Fl), or PPARc-Mac
neg (KO) macrophages were analyzed for
PPARcexpression. F. WT, PPARc
flox/flox, or PPARc-Mac
neg macrophages were co-cultured with CMT/167 cells in the presence or absence of
pioglitazone (10 mM). Cell lysates were analyzed for arginase I expression. Densitometry measurements showing normalized levels relative to control
are displayed below the western blot (average of three independent experiments). The densitometric analysis was performed using ImageJ software
(NIH, Bethesda, MD) as described in the Methods section. *P,0.05 vs WT control, **P,0.05 vs WT PIO. For all Westerns, b-actin was used as a loading
control.
doi:10.1371/journal.pone.0028133.g002
Figure 3. Targeted deletion of PPARcin macrophages inhibits lung cancer metastasis in an orthotopic mouse model of non-small
cell lung cancer. Following lethal irradiation, WT C57BL/6 mice received bone marrow from either PPARc-Mac
neg (KO) or PPARc
flox/flox (Flox) donor
mice as described in the ‘‘Methods’’ section. After 5 weeks recovery to allow engraftment, mice were placed on either pioglitazone-containing chow
or control chow for 1 week prior to tumor cell implantation and throughout the course of the experiment. Animals were injected with 10
5 CMT/167-
luc cells orthotopically as in Fig. 1. Four weeks after cancer cell inoculation, animals were imaged by bioluminescence and sacrificed. A. The number
of secondary lung tumors was quantitated by examination under a dissecting microscope. Tumors were counted by two independent blinded
observers. Data are means and s.e.m. of counts from 6–9 animals in each group. Mice receiving PPARc-Mac
neg bone marrow had significantly fewer
numbers of secondary lung tumors than mice receiving PPARc
flox/flox.* P ,0.05 vs Flox control. **P,0.05 vs Flox control. B. Representative histology
(H&E) is shown for secondary lung tumors from all 4 groups of animals. C. Tumor-bearing lung sections from WT PPARc
flox/flox or PPARc-Mac
neg mice
were immunohistochemically stained for arginase I (brown reaction color). Representative images are shown of lungs from all 4 groups of animals. D.
The number of arginase I-positive cells was quantitated by two independent blinded observers. Data are means and s.e.m. of counts from 6–9
animals in each group. Lungs from PPARc-Mac
neg mice on control chow showed a statistical decrease in arginase I positive cells; pioglitazone
increased the number of these cells to levels seen in PPARc
flox/flox mice. *P,0.05 vs Flox control.
doi:10.1371/journal.pone.0028133.g003
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28133Figure 4. Targeted deletion of PPARcin Macrophages inhibits lung cancer metastasis in a subcutaneous flank model of murine non-
small cell lung cancer. Following lethal irradiation, WT C57BL/6 mice received bone marrow from either PPARc-Mac
neg (KO) or PPARc
flox/flox (Flox)
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initiation in a chemical carcinogenesis model [22]. However, in
contrast to cancer initiation, which is largely mediated through
alterations in transformed epithelial cells, tumor progression and
metastasis involves critical interactions between the tumor and the
microenvironment. In the series of experiments we report here,
systemic administration of pioglitazone to mice accelerated tumor
progression and metastasis in two independent models of non-small
cell lung cancer. This was reflected in increases in both the
incidence and number of distant organ metastases that did not
correlate to primary tumor size. Importantly and contrary to what
was predicted, systemic administration of pioglitazone exerted no
survival benefits compared to control mice.
There are several potential reasons for these seemingly
unanticipated findings. First, as opposed to studies on human
NSCLC, our studies used murine lung cancer cells, which could
behave differently than human NSCLC cells. However, our
findings do not support this. Activation of PPARcin CMT/167
cells inhibited invasiveness and promoted a more differentiated
phenotype in 3D culture (Supporting Information S1), similar to
what we have observed in human NSCLC lines [10]. Instead, we
propose that the effects of pioglitazone on the acceleration of
tumor progression and metastasis are mediated largely through
effects on the tumor microenvironment. In fact, mice with a
targeted deletion of PPARc in myeloid lineages showed markedly
fewer secondary lung tumors in our orthotopic model, and fewer
lung metastases in our flank model. Furthermore pioglitazone
failed to increase pulmonary tumors in both knockout models.
These data to our knowledge are the first demonstration of an
important role of PPARc in the tumor microenvironment on
tumor progression and metastasis. Moreover, based on our in vitro
studies we propose that PPARc in macrophages is critical for the
conversion of macrophages into an alternatively activated
phenotype in the presence of cancer cells which has been shown
to promote metastasis [23]. Co-culture of WT macrophages with
cancer cells resulted in induction of arginase I expression, a classical
marker of alternatively activated macrophages, with further
increases in expression observed in the presence of pioglitazone;
this was markedly blunted if macrophages deficient in PPARc were
used for co-culture. Furthermore, in both metastasis models, the
number of arginase I-positive macrophages in the lung was
significantly decreased in mice with a targeted deletion of PPARc
in myeloid cells compared to controls indicating there is a strong
correlation between macrophage-specific PPARc activation and
metastasis progression.
Evidence from clinical and experimental studies indicates
macrophages promote solid tumor progression and metastasis.
Macrophages are educatedby the tumor microenvironment, so that
they adopt a trophic role that facilitates angiogenesis, matrix
breakdown and tumor cell motility, all of which are elements of
the metastatic process. There is evidence that tumor-associated
macrophages (TAMs) are alternatively activated, exhibiting upre-
gulated expression of intracellular enzymes such as arginase I [17].
Previousreportshaveshownthat arginaseIproduction inthe tumor
microenvironment by mature myeloid cells inhibits T-cell receptor
expression and antigen-specific T-cell responses [24]. Similarly,
tumor-infiltrating and tumor-educated dendritic cells have been
shown to suppress T cell responses through arginase I [25,26].
Murine ovarian cancer vascular leukocytes also require arginase I
activity for T cell suppression [27], and polymorphonuclear
granulocyte arginase has been shown to impair NK cell function
[28]. Collectively, these reports suggest arginase I plays a key role in
thesuppression ofboth the adaptiveandinnate immunesystemthus
promoting tumor progression.
The mechanisms by which tumors educate macrophages in the
tumor microenvironment and the role of PPARc in this interaction
remain poorly understood. Here we show that in vitro, CMT/167
cells induce the expression of arginase I in bone marrow-derived
macrophages.Moreover,treatmentwith pioglitazoneduringthe co-
culture period further enhances the expression of arginase I in
bone marrow-derived macrophages. Thus, cultured non-small
cell lung cancer cells promote macrophage differentiation
toward a phenotype that resembles the alternatively activated,
pro-tumorigenic state of TAMs. This switch is not dependent on
cell-cell contact, suggesting cancer cells produce diffusible factors
that induce phenotypic changes in macrophages. Our in vivo
findings of fewer arginase I-positive macrophages tumor-bearing
lungs of mice with targeted deletion of PPARc in myeloid cells are
consistent with the in vitro findings and point to a key role for
PPARc in the innate immune system.
While many articles indicate anti-tumorigenic effects of TZDs,
earlier studies have also demonstrated conflicting effects of TZDs in
colon carcinogenesis. These agents inhibit colon tumor growth in a
variety of immunocompromised xenograft models [29]. However,
in a genetic model of colon cancer, the APC
min mouse, TZDs
promoted tumor progression [30,31]. This is in contrast to studies
lookingattumorsinitiatedbyazoxymethane,whichareinhibitedby
TZDs [32]. Although the basis for these disparate effects has not
been established, it appears that activation of PPARc may have
opposing effects on cancer initiation vs progression in colon cancer,
similar to our results in lung cancer. It should be noted that TZDs
including pioglitazone have also been shown to act through ‘‘off-
target’’ pathways [33]. While our data using genetic deletion
strongly support a model in which effects in the TME are mediated
through ‘‘on-target’’ activation of PPARc, these studies do not
exclude a role for off-target effects. In particular, pioglitazone
inhibited primary tumor growth in PPARc-Mac
neg mice (Figure 4).
This could be a result of selective effects on tumor cells, but could
also involve PPARc-independent effects.
These findings have potential implications for patients taking
PPARc agonists, such as the TZD class of anti-diabetic agents. As
mentioned above, the retrospective study showing chemopreventive
donor mice as described in the ‘‘Methods’’ section. After 5 weeks recovery to allow engraftment, mice were placed on either pioglitazone-containing
chow or control chow for 1 week prior to tumor cell implantation and throughout the course of the experiment. Animals were then injected with 10
5
CMT/167-luc cells subcutaneously. Animals were imaged by bioluminescence, and sacrificed 4 weeks after cancer cell inoculation. A. Primary tumor
volumes in all the mice were measured using digital calipers. Data are means and s.e.m. of counts from 9–14 animals in each group. *P,0.05 vs Flox
Control. B. Incidence of lung metastasis was quantitated by examination under a dissecting microscope. Tumors were counted by two independent
blinded observers. Data are means and s.e.m. of counts from 9–14 animals in each group. Pioglitazone increased incidence of metastasis in WT mice,
but not in mice receiving PPARc-Mac
neg bone marrow. *P,0.05 vs Flox Control. **P,0.05 vs Flox Pio. C. Representative histology is shown for lung
metastases from all 4 groups of animals. D. Tumor-bearing lung sections from WT or PPARc-Mac
neg mice were immunohistochemically stained for
arginase I (brown reaction color). Representative images are shown of lungs from all 4 groups of animals. E. The number of arginase I-positive cells
was counted by two independent blinded observers. Data are means and s.e.m. of counts from 9–14 animals in each group with one section per
animal and 4 random fields per slide. The number of arginase I-positive cells was significantly decreased in PPARc-Mac
neg mice, both under control
conditions and in the presence of pioglitazone. *P,0.05 vs Flox Control.
doi:10.1371/journal.pone.0028133.g004
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treatment was initiated [9]. However, based on this study and
others, positive effects on chemoprevention of lung cancer may not
ensure similar positive outcomes in the therapeutic treatment of
patients with existing or prior lung cancer. Our data suggest that the
neteffectsofanagentsuchaspioglitazoneontumorprogression will
be a balance of anti-tumorigenic effects on the cancer cells, and




Wild type C57BL/6 mice were maintained in the Center for
Comparative Medicine at the University of Colorado Anschutz
Medical Campus. All procedures were performed under protocols
approved by the Institutional Animal Care and Use Committee
at the University of Colorado Denver (Protocols 06110(12)1E,
06110(06)1E and B-06110(07)1C)). For bone marrow transplant,
transgenic UBI-EGFP donor mice on a C57BL/6 background
were sacrificed, femurs and tibias were aseptically removed, and
bone marrow obtained by aspiration. Cells were suspended in
sterile HBSS+1% fetal calf serum. Recipient WT mice were
irradiated (900–1,200 RAD split doses) by X-ray source at 6 wks
of age. One hour following the second dose, isoflurane-
anesthetized, irradiated recipients were injected with donor
marrow via retro-orbital injection (2610
6 bone marrow-derived
cells/mouse). Mice were allowed to recover and fully engraft
donor bone marrow for 6 weeks prior to experimentation. UBI-
EGFP transgenic mice were used as donors to track bone marrow–
derived cells by GFP expression. Separate experiments were
performed in which WT mice received bone marrow from either
Lys-M-Cre6PPARc
flox/flox mice or control mice (PPARc
flox/flox).
Mice with targeted deletion of PPARc in macrophages were
generated by crossing PPARc
flox/flox mice (C57BL/6 background;
commercially available from JAX) with transgenic mice in which
Cre recombinase is under the control of the M lysozyme promoter
(Lys-M-Cre), similar to a previous report [34]. These mice, which
are Lys-M-Cre
+/2 PPARc
flox/flox are designated PPARc-Mac
neg.




Stable clones of CMT/167 cells, derived from a spontaneous
lung adenocarcinoma in C57BL/6 mice [13] expressing high
levels of firefly luciferase constitutively driven by an SV40
promoter (CMT/167-luc), were used for injection into animals
as described previously [5]. For bone marrow-derived macro-
phages, bone marrow–derived cells isolated from femurs and tibias
of PPARc
flox/flox or PPARc-Mac
neg mice were cultured in the
presence of 50 ng/mL M-CSF (R&D) to promote macrophage
maturation as previously described [16]. After 5 days in culture,
these cells have the morphology of macrophages, and are .95%
F4/80 positive.
Tumor cell injections
Mice were fed either control or pioglitazone-impregnated chow
(0.05%) for 7 days prior to cancer cell injection and throughout the
course of the experiment. This is an identical concentration used
for rosiglitazone in the setting of experimental pulmonary
hypertension [35]. By mass spectrometric analysis steady-state
levels were approximately 5000 ng/mL (data not shown), which is
somewhat higher than the 1500 ng/mL observed in human trials
[36]. In an orthotopic model, mice were directly injected with
CMT/167-luc cells (10
5 per 40 mL) suspended in 1.35 mg/mL
Matrigel Basement Membrane Matrix (BD Biosciences)/HBSS,
through the rib cage into the left lobe of the lung using 30-g
needles as described previously [5]. At time of sacrifice, mice were
injected i.p. with 300 mg/kg body weight luciferin (Caliper) before
sedation. The circulation was perfused and the lungs inflated with
heparinized PBS. The heart and lungs were removed en bloc and
the liver and brain were harvested for ex vivo bioluminescence
imaging. The left lobe was isolated from the remaining lung lobes
and imaged for bioluminescence separately; remaining lung lobes,
heart, mediastinal lymph nodes, liver, and brain were also imaged
separately using the IVIS Imaging System 50 Series (Caliper Life
Sciences/Xenogen Corp.). Primary tumor size was measured
using digital calipers and surface secondary pulmonary metastases
were counted under a dissecting microscope. After imaging, all
tissues were fixed with 4% paraformaldehyde (PFA) and
embedded in paraffin for morphological and immunohistochem-
ical analyses. Two additional methods were used to quantify
secondary pulmonary metastases: 1) H&E stained lung sections
were analyzed by counting all lobes for tumor formation; 3
sections per animal were counted by two blinded observers; 2) Ex
vivo luminescence incidence was scored for each lung lobe. In
addition, incidence of metastases to the liver and brain was scored
by luminescence and verified by H&E staining.
As a second model, cancer cells were implanted into the flank
subcutaneously as previously described [37]. Briefly, 10
5 CMT/
167-luc cells were injected as previously described [38]. Primary
tumor size was measured as a function of time by digital calipers,
and metastatic burden to the lungs was quantitated by examination
of the lungs under a dissecting microscope or by bioluminescence.
Immunofluorescence staining
For immunofluorescence labeling, PFA-fixed, paraffin-embed-
ded tissues were deparaffinized, rehydrated, and underwent
antigen retrieval by heating for 20 min at 115uC in a decloaking
chamber (Biocare). Sections were then exposed to specific
antibodies overnight at 4uC. After incubations with primary
antibodies, antigen/antibody complexes were visualized using
Alexa Fluor-568–coupled, Alexa Fluor-488–coupled, or Alexa-
647-coupled secondary antibodies (Molecular Probes); for triple
immunofluorescence, sections were sequentially incubated with
specific primary and secondary antibodies. Coverslips were
mounted with VectaShield medium containing 49,6-diamidino-
2-phenylindole to detect all cell nuclei (Vector Laboratories).
Sections were visualized using a Nikon inverted fluorescence
microscope equipped with Metamorph software or using a laser-
scanning confocal microscope (510 META NLO, Carl Zeiss,
Thornwood, NY) with LSM 510 software. Negative controls
included the use of mouse or rabbit IgG. Antibodies used include
polyclonal FITC-conjugated anti-GFP (1:200; Abcam), monoclo-
nal anti-Mac3 (1:50; BD Pharmingen), and polyclonal anti-
Arginase I (1:200; Santa Cruz). Quantification of macrophage
recruitment was determined by counting the number of Mac3-
positive cells in 406fields surrounding primary tumors or within
tumors. Three 406fields were counted per section; three sections
per animal were counted.
Measurement of mouse serum adiponectin levels
Eight-week old male C57BL/6 mice were fed either control
chow or pioglitazone-impregnated chow. The mice were sacrificed
either 7 or 23 days later, and serum was collected from each
mouse. Serum adiponectin levels were measured by ELISA (R&D
Systems Quantikine) as per manufacturer’s protocol.
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Bone marrow–derived macrophages (2610
6) from either WT,
PPARc
flox/flox or PPARc-Mac
neg mice were isolated and grown on
the bottom of 6-well plates for 4 days in the presence of M-CSF as
previously described [5,16]. CMT/167-luc cells (3610
4) were
grown on Transwell filters containing 0.4 mm pores (Corning).
Cells were placed in co-culture for 3 days, and lysates were
prepared in RIPA buffer and immunoblotted for arginase I or
iNOS. Arginase I antibody (Santa Cruz) was used at 1:200, iNOS
antibody (BD) was used at 1:1000 and b-actin (Sigma) was used at
1:5000 as a loading control. As a positive control macrophages
were stimulated for 24 hours with 20 ng/ml interferon-g/100 ng/
ml LPS to induce the M1 phenotype, and 20 ng/ml IL-4 (Sigma)
to induce the M2 phenotype. Relative abundance of protein was
determined by quantitative densitometry using ImageJ software
(NIH, Bethesda, MD). All Western Blot densitometry data on
arginase I were normalized to b-actin. The relative level of
arginase I was then normalized by the level of arginase I in WT
bone marrow-derived macrophages co-cultured with CMT/167-
luc cells in the absence of pioglitazone.
Statistical analyses
All values given represent mean values +/2 SE. To compare
the two groups, the Student’s t and Mann-Whitney U tests were
used (for normally or non-normally distributed data, respectively).
ANOVA was used to detect significant differences between
multiple groups. All P values are two-tailed; P values #0.05 were
considered significant.
Supporting Information
Figure S1 Effects of Pioglitazone on CMT/167 Cells. A.
CMT/167 cells were plated on Matrigel-coated 8 mm Transwells,
containing either 10 mM pioglitazone or vehicle (0.1% DMSO).
After 48 hours, cells that had invaded through the pores were
quantitated by DAPI staining. Pioglitazone decreased cell
invasiveness; *P,0.05 vs Control. B. CMT/167 cells were grown
in 3-dimensional Matrigel culture as previously described [10] in
the absence of presence of 10 mM pioglitazone. Cells were fixed
after 5 days, and regular spheroids, which are characteristic of
differentiated cancer cells were quantitated. Images are represen-
tative of 5 independent fields at 1006. Graph at the bottom
indicates quantitation. Pioglitazone increased the number of
differentiated organoid structures; *P,0.05 vs Control.
(DOC)
Figure S2 Rosiglitazone accelerates CMT/167 tumor
progression and metastasis in a mouse flank model of
NSCLC. A. Volume of primary flank tumors from C57BL/6
mice fed either normal chow or chow impregnated with
rosiglitazone (0.05%) at 28 days. B. Number of pulmonary
metastases in C57BL/6 mice fed either normal chow or
rosiglitazone chow at 28 days. C. Percentage of animals in each
group with lung metastases at 28 days. *P,0.05 vs Control.
(DOC)
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